Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AMIX
Upturn stock ratingUpturn stock rating

Autonomix Medical, Inc. Common Stock (AMIX)

Upturn stock ratingUpturn stock rating
$1.13
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: AMIX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $6.6

1 Year Target Price $6.6

Analysts Price Target For last 52 week
$6.6 Target price
52w Low $1.08
Current$1.13
52w High $19

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 0
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 5.71M USD
Price to earnings Ratio -
1Y Target Price 6.6
Price to earnings Ratio -
1Y Target Price 6.6
Volume (30-day avg) 2
Beta -
52 Weeks Range 1.08 - 19.00
Updated Date 08/15/2025
52 Weeks Range 1.08 - 19.00
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -5.33

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -95.2%
Return on Equity (TTM) -195.57%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -4984628
Price to Sales(TTM) -
Enterprise Value -4984628
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 5049890
Shares Floating 4371475
Shares Outstanding 5049890
Shares Floating 4371475
Percent Insiders 8.28
Percent Institutions 9.02

ai summary icon Upturn AI SWOT

Autonomix Medical, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Autonomix Medical, Inc. is a medical technology company focused on improving outcomes for patients undergoing surgical and therapeutic procedures. Their focus is on developing innovative technologies to enhance the precision and safety of these procedures. The company's history is relatively recent, with a focus on novel approaches to nerve stimulation and blocking.

business area logo Core Business Areas

  • Bioelectric Intermodulation (BIM) technology: Autonomix Medical's core technology platform aimed at targeting nerve interventions. It focuses on improving the safety and efficacy of procedures by guiding therapy delivery and reducing off-target effects.

leadership logo Leadership and Structure

Information on Autonomix Medical's leadership team and organizational structure can be found in their SEC filings and on their website.

Top Products and Market Share

overview logo Key Offerings

  • Autonomic Modulation System (AMS): Autonomix Medical is developing an AMS. It is too early to have market share or competitors as it's under development.

Market Dynamics

industry overview logo Industry Overview

The medical device industry is experiencing growth fueled by technological advancements, an aging population, and increasing demand for minimally invasive procedures. The neuromodulation market is a significant segment, focusing on devices that stimulate or block nerves to treat various conditions.

Positioning

Autonomix Medical aims to be a leader in targeted nerve intervention technologies, leveraging its unique BIM technology to offer more precise and effective solutions. This technology can differentiate it from competitors using traditional nerve stimulation or ablation methods.

Total Addressable Market (TAM)

The TAM for neuromodulation and targeted nerve intervention is substantial, estimated to be in the billions of dollars. Autonomix Medical is positioned to capture a share of this market with its innovative technology, contingent on regulatory approvals and successful commercialization.

Upturn SWOT Analysis

Strengths

  • Proprietary Bioelectric Intermodulation (BIM) technology
  • Potential for improved precision and safety in nerve interventions
  • Focus on unmet clinical needs in neuromodulation
  • Experienced management team

Weaknesses

  • Limited commercialized products
  • Dependence on regulatory approvals
  • Need for additional funding
  • Limited brand recognition

Opportunities

  • Expansion into new therapeutic areas
  • Partnerships with larger medical device companies
  • Increasing adoption of minimally invasive procedures
  • Growing market for neuromodulation therapies

Threats

  • Competition from established medical device companies
  • Technological obsolescence
  • Regulatory hurdles
  • Economic downturn affecting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • MDLZ
  • ABT
  • BSX

Competitive Landscape

Autonomix Medical faces competition from larger, established medical device companies with broader product portfolios and greater resources. Its competitive advantage lies in its proprietary BIM technology, which offers the potential for more precise and effective nerve interventions.

Growth Trajectory and Initiatives

Historical Growth: Autonomix Medical's historical growth is reflected in its progress in developing its technology and conducting clinical trials.

Future Projections: Future growth projections are dependent on successful regulatory approvals, commercialization of its products, and market adoption.

Recent Initiatives: Recent initiatives include ongoing clinical trials, development of its AMS platform, and securing funding.

Summary

Autonomix Medical is a developing medical technology company with a promising platform technology. The company is still in the early stages, and faces competition from larger players. Regulatory approvals and successful commercialization are crucial for future success. Growth depends on market adoption and new opportunities.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Market Research Reports

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Market share data and other information are based on available resources and estimates. Investment decisions should be made in consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Autonomix Medical, Inc. Common Stock

Exchange NASDAQ
Headquaters The Woodlands, TX, United States
IPO Launch date 2024-01-29
President, CEO & Director Mr. Bradley Hauser
Sector Healthcare
Industry Medical Devices
Full time employees 8
Full time employees 8

Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company's technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.